Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...